Intazumab 30 mg Injection 1's

Intazumab 30 mg Injection 1's is an anti-cancer medicine used in the treatment of Breast cancer. Cancer is a disease where the cells grow abnormally and divide uncontrollably. The abnormal growth of cancer (malignant) cells in the breast is known as breast cancer. Intazumab 30 mg Injection 1's is combined with trastuzumab and docetaxel for treating patients with HER2-positive metastatic breast cancer who have not received any chemotherapy for metastatic breast cancer. This medicine is also used in combination with docetaxel and trastuzumab as a neoadjuvant treatment of breast cancer in patients with HER2-positive (human epidermal growth factor receptor 2) or as part of a complete treatment regimen for early breast cancer.

Intazumab 30 mg Injection 1's contains Pertuzumab as a active ingredient which belongs to the class of monoclonal antibodies. It works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis.

Intazumab 30 mg Injection 1's may cause certain side effects such as fatigue, nausea, headache, vomiting, dizziness, hair loss, constipation, dry skin, myalgia, upper respiratory tract infections, diarrhea, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare doctor will administer Intazumab 30 mg Injection 1's. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.

Intazumab 30 mg Injection 1's should be avoided if you are allergic to it or any other components of this medicine. Intazumab 30 mg Injection 1's may cause left ventricular dysfunction, anaphylaxis, or hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. If any changes or hypersensitivity reactions occur, treatment should be discontinued. Inform your doctor if you have any cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Intazumab 30 mg Injection 1's is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand. The use of Intazumab 30 mg Injection 1's along with the doxorubicin-containing regimen is not established. Hence, if you are on such treatment, inform your doctor before starting the treatment. Intazumab 30 mg Injection 1's is not recommended for use in children as the safety and efficacy are not established.

Intazumab 30 mg Injection 1's is used in the treatment of Breast Cancer. The detailed uses of Intazumab 30 mg Injection 1's are as follows:

• Metastatic HER2-Positive Breast Cancer: Intazumab 30 mg Injection 1's is used in combination with trastuzumab and docetaxel as a first-line treatment for patients who haven’t received prior anti-HER2 therapy for metastatic disease.
• Neoadjuvant Therapy: Intazumab 30 mg Injection 1's is given before surgery to shrink tumors in locally advanced or early-stage HER2-positive breast cancer.
• Adjuvant Therapy: Intazumab 30 mg Injection 1's is used after surgery in patients with early-stage HER2-positive breast cancer who are at high risk of recurrence.

• Follow your doctor’s instructions on the dosage and timing of this medication.
• Intazumab 30 mg Injection 1's will be administered by a nurse or doctor.
• Do not self-administer.

Intazumab 30 mg Injection 1's contains Pertuzumab, which belongs to the class of monoclonal antibodies. It works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of apoptosis. Intazumab 30 mg Injection 1's is used in combination with trastuzumab and docetaxel for the treatment of breast cancer.

Intazumab 30 mg Injection 1's should be avoided if you are allergic to it or any other components of this medicine. Intazumab 30 mg Injection 1's may cause left ventricular dysfunction, anaphylaxis, or hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. If any changes or hypersensitivity reactions occur, treatment should be discontinued. Inform your doctor if you have any cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Intazumab 30 mg Injection 1's is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand. The use of Intazumab 30 mg Injection 1's along with the doxorubicin-containing regimen is not established. Hence, if you are on such treatment, inform your doctor before starting the treatment. Intazumab 30 mg Injection 1's is not recommended for use in children as the safety and efficacy are not established.